Goldhagen Brian E, Goldhardt Raquel
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.
Curr Ophthalmol Rep. 2017 Jun;5(2):141-148. doi: 10.1007/s40135-017-0133-4. Epub 2017 May 8.
PURPOSE OF REVIEW WHAT IS THE GOAL OF YOUR PAPER? WHAT QUESTIONS DID YOU SEEK TO ANSWER?: The goal of this paper is to provide a comprehensive review of the management options for central serous chorioretinopathy (CSCR).
The majority of cases of acute CSCR may be managed with observation and cessation of corticosteroids, if possible, as well as life-style modifications including stress reduction and control of hypertension. The management of chronic disease is more challenging and may include either medication or laser-based treatment.
SUMMARY WHAT ANSWERS DID YOU FIND? WHAT ARE THE MAJOR TAKEAWAYS/CONCLUSIONS OF YOUR EXAMINATION? WHAT’S THE IMPACT ON FUTURE RESEARCH?: Management of CSCR necessitates an individualized and selective treatment approach. There is overall poor evidence for the use of systemic and intravitreal medications. From this class of treatments, mineralocorticoid receptor antagonists appear to have the greatest potential. Although conventional thermal photocoagulation may be used in select cases, the most promising treatment options at this time for chronic CSCR are photodynamic therapy, either half-dose or half-fluence, and non-damaging (subthreshold) retinal laser therapy.
综述目的 你的论文目标是什么？你试图回答哪些问题？：本文的目的是对中心性浆液性脉络膜视网膜病变（CSCR）的治疗选择进行全面综述。
近期研究结果 总结你主题的最新研究：大多数急性CSCR病例可通过观察以及尽可能停用皮质类固醇激素，并进行生活方式调整，包括减轻压力和控制高血压来治疗。慢性病的治疗更具挑战性，可能包括药物治疗或激光治疗。
总结 你找到了哪些答案？你研究的主要收获/结论是什么？对未来研究有何影响？：CSCR的治疗需要个性化和选择性的治疗方法。使用全身和玻璃体内药物的总体证据不足。在这类治疗中，盐皮质激素受体拮抗剂似乎具有最大潜力。虽然传统的热光凝可用于某些病例，但目前慢性CSCR最有前景的治疗选择是光动力疗法，即半剂量或半能量，以及非破坏性（阈下）视网膜激光治疗。
